Literature DB >> 2109672

Recurrent postoperative endophthalmitis.

G A Stern1, H M Engel, W T Driebe.   

Abstract

We treated five patients for postoperative endophthalmitis who demonstrated an initially good response to intravitreal management of their infection and then suffered a later recurrence. Four of the five patients received a single intravitreal injection of antibiotics as the only intravitreal therapy, and the fifth patient received a single antibiotic injection in addition to a partial vitrectomy. All recurrent infections occurred between 10 and 21 days after the original intravitreal injection of antibiotics. At the time of the recurrence, all five patients remained culture positive with the same organism that was initially isolated. The bacterial species isolated were S. epidermidis, group D streptococcus, P. acnes, P. mirabilis, and P. aeruginosa. All patients were ultimately sterilized with repeated intravitreal injections of antibiotics, vitrectomy, and/or intraocular lens removal. Factors that were related to recurrent infection were marginal susceptibility of the organism to the originally injected antibiotics, infection with a slowly replicating organism, and infection with a gram-negative bacillus. A single intravitreal injection of antibiotics may only partially treat bacterial endophthalmitis. Patients should be observed for at least 3 weeks following treatment of endophthalmitis for recurrence of their infection, and aggressive management, including vitrectomy and repeated intravitreal injections of antibiotics, should be used to treat recurrent infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109672

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  13 in total

Review 1.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

2.  Persistently Vitreous Culture-Positive Exogenous Bacterial Endophthalmitis.

Authors:  Ella H Leung; Ajay E Kuriyan; Harry W Flynn; Darlene Miller; Laura C Huang
Journal:  Am J Ophthalmol       Date:  2016-02-26       Impact factor: 5.258

3.  Delayed- versus acute-onset endophthalmitis after cataract surgery.

Authors:  Anita R Shirodkar; Avinash Pathengay; Harry W Flynn; Thomas A Albini; Audina M Berrocal; Janet L Davis; Geeta A Lalwani; Timothy G Murray; William E Smiddy; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2011-10-25       Impact factor: 5.258

Review 4.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 6.  Aggressive management of an epidemic of chronic pseudophakic endophthalmitis: results and literature survey.

Authors:  N K Rogers; P D Fox; B A Noble; K Kerr; T Inglis
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

7.  Experimental postoperative endophthalmitis.

Authors:  R K Forster
Journal:  Trans Am Ophthalmol Soc       Date:  1992

8.  Adherence of bacteria to intraocular lenses: a prospective study.

Authors:  A Doyle; B Beigi; A Early; A Blake; P Eustace; R Hone
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

9.  Clinical presentations and comparative outcomes of primary versus deferred intraocular lens explantation in delayed-onset endophthalmitis.

Authors:  Vivek P Dave; Avinash Pathengay; Savitri Sharma; Vishal Govindhari; Roshni Karolia; Rajeev R Pappuru; Taraprasad Das
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

10.  Pathogens in the Meibomian gland and conjunctival sac: microbiome of normal subjects and patients with Meibomian gland dysfunction.

Authors:  Xiaodan Jiang; Aihua Deng; Jiarui Yang; Hua Bai; Zhao Yang; Jie Wu; Huibin Lv; Xuemin Li; Tingyi Wen
Journal:  Infect Drug Resist       Date:  2018-10-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.